Asset Details
Do you wish to reserve the book?
The European Response to the CCR5 Patent
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The European Response to the CCR5 Patent
Do you wish to request the book?
The European Response to the CCR5 Patent
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Book Chapter
The European Response to the CCR5 Patent
2015
Overview
Thus far I have told the American story of the CCR5 patent. It possesses a European lineage, as well. In chapter 2, it was noted that the Belgian company Euroscreen is the licensing agent for the CCR5 patent portfolio. Patent holders generally apply for patents in (at least) the three major markets—the United States, Europe, and Japan. Euroscreen filed its two European patents on February 28, 1997, both with priority dates of March 1, 1996. The first patent (EP 0883687) was granted for the CCR5 receptor, derivatives thereof, and their uses and had a European Patent Bulletin publication date
